New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE/MYSIMBA Amidst GLP-1 Supply Issues
July 23, 2024 – BioManufacturing, Biotechnology, Other – Currax Pharmaceuticals, anti-obesity drugs, manufacturing
23 July 2024 — Tennessee, US — Currax Pharmaceuticals LLC today announced the approval of additional manufacturing site for CONTRAVE/MYSIMBA in the European Union (EU) and European Union Economic Areas (EEA).
The new site doubles the current production capacity of CONTRAVE/MYSIMBA and ensures continuity of supply, and the site has capacity to increase production when needed. An application to the US Food & Drug Administration (FDA) for approval of this additional site is scheduled for Q3 2024. As supply constraints continue for GLP-1 anti-obesity medications, it is critical that patients have reliable supply and access to other non-GLP-1 treatment options.
CONTRAVE is the only anti-obesity medication in its class, the Reward System Modulator class (RMS), that is specifically designed to both reduce hunger and control cravings. Available in both the US and Europe for more than 10 years, CONTRAVE has shown to be both safe and effective for the treatment of obesity with a collective use of greater than 650,000 patient years. CONTRAVE is an important and unique treatment option for physicians and patients because not only it is effective, but it is also affordable; with a price that is 40 to 60% less than the leading branded medications. The most common GI-related side effects were generally mild and transient in nature, and subsided in the first 2-4 weeks.
“According to the World Health Organization (WHO), one in eight people are living with obesity, and we believe those patients deserve consistent access to medications to treat their disease,” said George Hampton, president and CEO of Currax Pharmaceuticals. “Access to medications is one of our core values and reliability of supply is a critical component to access. We continue to invest heavily in our ability to supply the unprecedented increase in worldwide demand. This is especially important at a time when the GLP-1 companies are plagued with chronic supply issues.”
As treatment rates expand, it is critical that medication is available for both commercial and clinical programmes. The primary clinical programme for CONTRAVE is the INFORMUS trial. It is designed to further characterize the long-term cardiovascular safety of CONTRAVE, and within the first six months of the trial there have been more than 1300 patients enrolled and randomised.
About Currax Pharmaceuticals
Currax Pharmaceuticals is a specialty pharmaceutical business focused on addressing the #1 and #2 causes of preventable death in the US: smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE (naltrexone HCl/bupropion HCl), ONZETRA Xsail (sumatriptan nasal powder), Silenor (doxepin), Treximet (sumatriptan/naproxen sodium), and the authorised generic of Treximet. Visit: www.curraxpharma.com.
